Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qiagen NVQGEN -0.77%74 Equity-to-Asset is 0.57 as of Jun. 2026, which is 8% above its 10-year median of 0.53. GuruFocus rates QGEN with a GF Score™ of 74/100 and a GF Value™ of $49.37 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Qiagen NV ranks worse than 52.61% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Qiagen NV's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $3,358 Mil. Qiagen NV's Total Assets for the quarter that ended in Jun. 2026 was $5,889 Mil.
Therefore, Qiagen NV's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.57.
The historical rank and industry rank for Qiagen NV's Equity-to-Asset or its related term are showing as below:
QGEN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46 Med: 0.53 Max: 0.63
Current: 0.57
During the past 13 years, the highest Equity to Asset Ratio of Qiagen NV was 0.63. The lowest was 0.46. And the median was 0.53.
QGEN's Equity-to-Asset is ranked worse than 52.61% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.6
vs QGEN: 0.57
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Qiagen NV Equity-to-Asset Related Terms
Qiagen NV Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QGEN vs TWST, RDNT, SHC: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Qiagen NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Qiagen NV's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Qiagen NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (QGEN) has a Equity-to-Asset of 0.57 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Qiagen NV and its competitors. This is near median its historical median of 0.53. Over the past decade, Qiagen NV's Equity-to-Asset has ranged from 0.46 to 0.63. According to the industry distribution chart, Qiagen NV ranks #111 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Qiagen NV's Equity-to-Asset too high?
Qiagen NV's current Equity-to-Asset of 0.57 is near median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 0.63. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Qiagen NV's value of 0.57 is 5% below this industry median. Based on the distribution chart, Qiagen NV ranks #111 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Qiagen NV has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Equity-to-Asset compare to TWST and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #111 out of 211 companies for Equity-to-Asset. This places Qiagen NV in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Qiagen NV's value of 0.57 is 5% below this benchmark. Historically, Qiagen NV's own Equity-to-Asset has ranged from 0.46 to 0.63 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.60, Qiagen NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current Equity-to-Asset of 0.57 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current Equity-to-Asset is 0.57, which is near median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (QGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.37, compared to a current price of $43.86 — trading 11.2% below its estimated fair value. The current Equity-to-Asset is 0.57, which is near median its 10-year median of 0.53 and 5% below the Medical Diagnostics & Research industry median of 0.60. Qiagen NV's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Qiagen NV (QGEN), the current Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (QGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of $43.86 is trading 11.2% below its estimated GF Value™ of $49.37.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for QGEN:
Equity-to-Asset: 0.57 (near median its 10-year median of 0.53)
GF Value™: $49.37 vs. price of $43.86 (11.2% below fair value)
Industry Position: 5% below the Medical Diagnostics & Research median (#111 of 211)
No single metric tells the full story. See the QGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
74GF Score
Get the complete analysis for QGEN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QGEN has been successfully added to your 
